Diabetic macular edema: Therapeutic options

Diabetes Therapy

Volumn 3, Issue 1, 2012, Pages 1-14

  Kulkarni, Amol D ^a   Ip, Michael S ^b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Antivascular endothelial growth factor; Corticosteroids; Diabetic macular edema; Intravitreal injection; Laser photocoagulation; Vitrectomy

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; CELECOXIB; CORTICOSTEROID; CORTICOSTEROID DERIVATIVE; CYCLOOXYGENASE 2 INHIBITOR; DEXAMETHASONE; FLUOCINOLONE ACETONIDE; GLYCOSYLATED HEMOGLOBIN; PEGAPTANIB; PLACEBO; RANIBIZUMAB; RUBOXISTAURIN; STEROID; TRIAMCINOLONE; VASCULOTROPIN ANTIBODY;

AGE; CATARACT; COLOR VISION DEFECT; DIABETIC MACULAR EDEMA; DIABETIC PATIENT; DISEASE DURATION; DRUG DELIVERY SYSTEM; DRUG MEGADOSE; DRUG USE; HUMAN; HYPERLIPIDEMIA; INTRAOCULAR PRESSURE; LASER COAGULATION; LOADING DRUG DOSE; LOW DRUG DOSE; METAPLASIA; NONHUMAN; OPTICAL COHERENCE TOMOGRAPHY; PATHOGENESIS; PIGMENT EPITHELIUM; PRIORITY JOURNAL; PROGNOSIS; PROTEINURIA; PSEUDOPHAKIA; RETINA FLUORESCEIN ANGIOGRAPHY; REVIEW; RISK FACTOR; SCAR FORMATION; SCOTOMA; SEX DIFFERENCE; SIDE EFFECT; SUBRETINAL NEOVASCULARIZATION; SYSTOLIC BLOOD PRESSURE; UVEITIS; VISUAL ACUITY; VISUAL IMPAIRMENT; VITRECTOMY;

EID: 84861881301     PISSN: 18696953     EISSN: 18696961     Source Type: Journal    
DOI: 10.1007/s13300-012-0002-y     Document Type: Review

References (86)

1. Aiello LM. Perspectives on diabetic retinopathy. Am J Ophthalmol. 2003;136:122-35.
2. Centers for Disease Control and Prevention. Blindness caused by diabetes-Massachusetts, 1987-1994. JAMA. 1996;276:1865-6.
3. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol. 1985;103:1796-806.
4. Moss SE, Klein R, Klein BE. Ten-year incidence of visual loss in a diabetic population. Ophthalmology. 1994;101:1061-70.
5. Augustin A, Loewenstein A, Kuppermann BD. Macular edema. General pathophysiology. Dev Ophthalmol. 2010;47:10-26.
6. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321: 405-12.
7. Adler AI, Stratton IM, Neil HA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ. 2000;321:412-9.
8. McDonald HR, Schatz H. Visual loss following panretinal photocoagulation for proliferative diabetic retinopathy. Ophthalmology. 1985;92: 388-93.
9. Aiello LP, Bursell SE, Clermont A, et al. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. Diabetes. 1997;46:1473-80.
10. Antonetti DA, Barber AJ, Hollinger LA, et al. Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occludin 1. A potential mechanism for vascular permeability in diabetic retinopathy and tumors. J Biol Chem. 1999; 274:23463-7.
11. Hikichi T, Fujio N, Akiba J, et al. Association between the short-term natural history of diabetic macular edema and the vitreomacular relationship in type II diabetes mellitus. Ophthalmology. 1997;104:473-8.
12. Browning DJ, Altaweel MM, Bressler NM, et al. Diabetic macular edema: what is focal and what is diffuse? Am J Ophthalmol. 2008;146:649-55.
13. Danis RP, Hubbard LD. Imaging of diabetic retinopathy and diabetic macular edema. Curr Diab Rep. 2011;11:236-43.
14. Early Treatment Diabetic Retinopathy Study Research Group. Classification of diabetic retinopathy from fluorescein angiograms. ETDRS report number 11. Ophthalmology. 1991;98(Suppl. 5):807-22.
15. Kylstra JA, Brown JC, Jaffe GJ, et al. The importance of fluorescein angiography in planning laser treatment of diabetic macular edema. Ophthalmology. 1999;106:2068-73.
16. Al-latayfeh MM, Sun JK, Aiello LP. Ocular coherence tomography and diabetic eye disease. Semin Ophthalmol. 2010;25: 192-7.
17. Baskin DE. Optical coherence tomography in diabetic macular edema. Curr Opin Ophthalmol. 2010;21:172-7.
18. Diabetic Retinopathy Clinical Research Network, Browning DJ, Glassman AR, Aiello LP, et al. Relationship between optical coherence tomography-measured central retinal thickness and visual acuity in diabetic macular edema. Ophthalmology. 2007;114:525-36.
19. Witkin AJ, Brown GC. Update on nonsurgical therapy for diabetic macular edema. Curr Opin Ophthalmol. 2011;22:185-9.
20. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703-13. (erratum in: BMJ. 1999;318:29).
21. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression oflong-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-86.
22. Diabetes Control and Complications Trial Research Group. Progression of retinopathy with intensive versus conventional treatment in the diabetes control and complications trial. Ophthalmology. 1995;102:647-61.
23. Klein R, Klein BE, Moss SE, et al. The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema. Ophthalmology. 1984;91:1464-74.
24. Klein R, Klein BE, Moss SE, et al. Is blood pressure a predictor of the incidence or progression of diabetic retinopathy? Arch Intern Med. 1989;149:2427-32.
25. Gordon B, Chang S, Kavanagh M, et al. The effects of lipid lowering on diabetic retinopathy. Am J Ophthalmol. 1991;112:385-91.
26. Danis RP, Sheetz MJ. Ruboxistaurin: PKC-beta inhibition for complications of diabetes. Expert Opin Pharmacother. 2009;10:2913-25.
27. Aiello LP, Vignati L, Sheetz MJ, et al. Oral protein kinase C β inhibition using ruboxistaurin: efficacy, safety, and causes of vision loss among 813 patients (1,392 eyes) with diabetic retinopathy in the Protein Kinase C β Inhibitor-Diabetic Retinopathy Study and the Protein kinase C β Inhibitor-Diabetic Retinopathy Study 2. Retina. 2011;31:2084-94.
28. Gardner TW, Antonetti DA, Barber AJ, et al. New insights into the pathophysiology of diabetic retinopathy: potential cell-specific therapeutic targets. Diabetes Technol Ther. 2000;2:601-8.
29. Chin MS, Nagineni CN, Hooper LC, et al. Cyclooxygenase-2 gene expression and regulation in human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci. 2001;42:2338-46.
30. Lorenzi M, Gerhardinger C. Early cellular and molecular changes induced by diabetes in the retina. Diabetologia. 2001;44:791-804.
31. Naveh-Floman N, Weissman C, Belkin M. Arachidonic acid metabolism by retinas of rats with streptozotocin-induced diabetes. Curr Eye Res. 1984;3:1135-9.
32. Ershov AV, Bazan NG. Induction of cyclooxygenase-2 gene expression in retinal pigment epithelium cells by photoreceptor rod outer segment phagocytosis and growth factors. J Neurosci Res. 1999;58:254-61.
33. Chew EY, Kim J, Coleman HR, et al. Preliminary assessment of celecoxib and microdiode pulse laser treatment of diabetic macular edema. Retina. 2010;30:459-67.
34. Ahmadi MA, Lim JI. Update on laser treatment of diabetic macular edema. Int Ophthalmol Clin. 2009;49:87-94.
35. Early Treatment Diabetic Retinopathy Study Research Group. Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 2. Ophthalmology. 1987;94:761-74.
36. Schatz H, Madeira D, McDonald HR, et al. Progressive enlargement of laser scars following grid laser photocoagulation for diffuse diabetic macular edema. Arch Ophthalmol. 1991;109:1549-51.
37. Roider J. Laser treatment of retinal diseases by subthreshold laser effects. Semin Ophthalmol. 1999;14:19-26.
38. Moorman CM, Hamilton AM. Clinical applications of the MicroPulse diode laser. Eye. 1999;13:145-50.
39. Sivaprasad S, Elagouz M, McHugh D, et al. Micropulsed diode laser therapy: evolution and clinical applications. Surv Ophthalmol. 2010; 55:516-30.
40. Kozak I, Oster SF, Cortes MA, et al. Clinical evaluation and treatment accuracy in diabetic macular edema using navigated laser photocoagulator NAVILAS. Ophthalmology. 2011;118:1119-24.
41. Schwartz SG, Flynn HW Jr, Scott IU. Pharmacotherapy for diabetic retinopathy. Expert Opin Pharmacother. 2009;10:1123-31.
42. Nauck M, Karakiulakis G, Perruchoud AP, et al. Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells. Eur J Pharmacol. 1998;341:309-15.
43. Nauck M, Roth M, Tamm M, et al. Induction of vascular endothelial growth factor by platelet-activating factor and platelet-derived growth factor is downregulated by corticosteroids. Am J Respir Cell Mol Biol. 1997;16:398-406.
44. Jonas JB, Kreissig I, Sofker A, et al. Intravitreal injection of triamcinolone for diffuse diabetic macular edema. Arch Ophthalmol. 2003;121: 57-61.
45. Martidis A, Duker JS, Greenberg PB, et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology. 2002;109:920-7.
46. Massin P, Audren F, Haouchine B, et al. Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: preliminary results of a prospective controlled trial. Ophthalmology. 2004;111:218-24.
47. Gillies MC, McAllister IL, Zhu M, et al. Intravitreal triamcinolone prior to laser treatment of diabetic macular edema: 24-month results of a randomized controlled trial. Ophthalmology. 2011;118: 866-72.
48. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology. 2008;115:1447-9. (1449.e1-10).
49. Lam DS, Chan CK, Mohamed S, et al. Intravitreal triamcinolone plus sequential sequential grid laser versus triamcinolone or laser alone for treating diabetic macular edema: six-month outcomes. Ophthalmology. 2007;114:2162-7.
50. Avitabile T, Longo A, Reibaldi A. Intravitreal triamcinolone compared with macular laser grid photocoagulation for the treatment of cystoid macular edema. Am J Ophthalmol. 2005;140: 695-702.
51. Kang SW, Sa HS, Cho HY, Kim JI. Macular grid photocoagulation after intravitreal triamcinolone acetonide for diffuse diabetic macular edema. Arch Ophthalmol. 2006;124:653-8.
52. Diabetic Retinopathy Clinical Research Network. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010;117:1064-77.
53. Pearson A, Levy B. The Fluocinolone Acetonide Implant Study Group. Fluocinolone acetonide intravitreal implant to treat DME: 2-year results of a multicenter clinical trial. Invest Ophthalmol Vis Sci. 2005;46. (E-Abstract 1795).
54. Campochiaro PA, Hafiz G, Shah SM, et al. Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert. Ophthalmology. 2010;117: 1393-9.
55. Campochiaro PA, Brown DM, Pearson A, et al. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology. 2011;118:626-35.
56. Augustin AJ. Upcoming therapeutic advances in diabetic macular edema: an intravitreal dexamethasone drug delivery system. Expert Opin Drug Deliv. 2011;8:271-9.
57. Haller JA, Kuppermann BD, Blumenkranz MS, et al. Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. Arch Ophthalmol. 2010;128:289-96.
58. Butcher JM, Austin M, McGalliard J, et al. Bilateral cataracts and glaucoma induced by long term use of steroid eye drops. BMJ. 1994;309:43.
59. Grover D, Li TJ, Chong CC. Intravitreal steroids for macular edema in diabetes. Cochrane Database Syst Rev. 2008;1:CD005656.
60. Vinores SA, Youssri AI, Luna JD, et al. Upregulation of vascular endothelial growth factor in ischemic and non-ischemic human and experimental retinal disease. Histol Histopathol. 1997;12:99-109.
61. Eyetech Study Group. Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina. 2002;22:143-52.
62. Sultan MB, Zhou D, Loftus J, et al. A phase 2/3, multicenter, randomized, double-masked, 2-year trial of pegaptanib sodium for the treatment of diabetic macular edema. Ophthalmology. 2011; 118:1107-18.
63. Ferrara N, Hillan KJ, Gerber HP, et al. Discovery and development of bevacizumab, an anti-VEGFantibody for treating cancer. Nat Rev Drug Discov. 2004;3:391-400.
64. Diabetic Retinopathy Clinical Research Network. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology. 2007;114:1860-7.
65. Soheilian M, Ramezani A, Obudi A, et al. Randomized trial of intravitreal bevacizumabalone or combined with triamcinolone versusmacular photocoagulation in diabetic macular edema. Ophthalmology. 2009;116:1142-50.
66. Arevalo JF, Sanchez JG, Wu L, et al. Primary intravitreal bevacizumab for diffuse diabetic macular edema: the Pan-American Collaborative Retina Study Group at 24 months. Ophthalmology. 2009;116:1488-97. (1497.e1).
67. Faghihi H, Roohipoor R, Mohammadi SF, et al. Intravitreal bevacizumab versus combined bevacizumab-triamcinolone versus macular laser photocoagulation in diabetic macular edema. Eur J Ophthalmol. 2008;18:941-8.
68. Michaelides M, Kaines A, Hamilton RD, et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. Ophthalmology. 2010;117:1078-86.
69. Kaiser PK. Antivascular endothelial growth factor agents and their development: therapeutic implications in ocular diseases. Am J Ophthalmol. 2006;142:660-8.
70. Patel RD, Momi RS, Hariprasad SM. Review of ranibizumab trials for neovascular age-related macular degeneration. Semin Ophthalmol. 2011; 26:372-9.
71. Channa R, Smith M, Campochiaro PA. Treatment of macular edema due to retinal vein occlusions. Clin Ophthalmol. 2011;5:705-13.
72. Nguyen QD, Shah SM, Khwaja AA, et al. Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study. Ophthalmology. 2010;117:2146-51.
73. Mitchell P, Bandello F, Schmidt-Erfurth U, et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011;118: 615-25.
74. Genentech Press release. Available at: http://www.gene.com/gene/news/press-releases/display.do?method=print&id=13527. Accessed June 28, 2011.
75. Stewart MW. Aflibercept (VEGF-TRAP): the next anti-VEGF drug. Inflamm Allergy Drug Targets. 2011;10:497-508.
76. Do DV, Schmidt-Erfurth U, Gonzalez VH, et al. The DA VINCI Study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema. Ophthalmology. 2011;118:1819-26.
77. Nasrallah FP, Jalkh AE, Van Coppenolle F, et al. The role of the vitreous in diabetic macular edema. Ophthalmology. 1988;95:1335-9.
78. Ikeda T, Sato K, Katano T, et al. Attached posterior hyaloid membrane and the pathogenesis of honeycombed cystoid macular edema in patients with diabetes. Am J Ophthalmol. 1999;127: 478-9.
79. Tachi N. Surgical management of macular edema. Semin Ophthalmol. 1998;13:20-30.
80. Pendergast SD. Vitrectomy for diabetic macular edema associated with a taut premacular posterior hyaloid. Curr Opin Ophthalmol. 1998;9:71-5.
81. Pendergast SD, Hassan TS, Williams GA, et al. Vitrectomy for diffuse diabetic macular edemaassociated with a taut premacular posterior hyaloid. Am J Ophthalmol. 2000;130:178-86.
82. Yamamoto T, Akabane N, Takeuchi S. Vitrectomy for diabetic macular edema: the role of posterior vitreous detachment and epimacular membrane. Am J Ophthalmol. 2001;132:369-77.
83. Harbour JW, Smiddy WE, Flynn HW Jr, et al. Vitrectomy for diabetic macular edema associated with a thickened and taut posterior hyaloid membrane. Am J Ophthalmol. 1996;121:405-13.
84. Diabetic Retinopathy Clinical Research Network Writing Committee, Haller JA, Qin H, Apte RS, et al. Vitrectomy outcomes in eyes with diabetic macular edema and vitreomacular traction. Ophthalmology. 2010;117:1087.e3-1093.e3.
85. Lewis H, Abrams GW, Blumenkranz MS, et al. Vitrectomy for diabetic macular traction and edema associated with posterior hyaloidal traction. Ophthalmology. 1992;99:753-9.
86. Tachi N, Ogino N. Vitrectomy for diffuse macular edema in cases of diabetic retinopathy. Am J Ophthalmol. 1996;122:258-60.